toolName,toolType,_pmid,_doi,_publicationTitle,_year,_confidence,_usageType,nf_specific,completeness_score,priority,strainNomenclature,animalModelGeneticDisorder,animalModelOfManifestation,targetAntigen,hostOrganism,clonality,organ,cellLineGeneticDisorder,cellLineManifestation,cellLineCategory,insertName,vectorType,vectorBackbone,promoter,softwareName,softwareType,softwareVersion,sourceRepository,modelType,derivationSource,cellTypes,organoidType,modelSystemType,patientDiagnosis,hostStrain,tumorType,assessmentName,assessmentType,targetPopulation,diseaseSpecific,numberOfItems,_context,filter_reason
dLight1.2,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dLight1.2,Viral,AAV,hSyn,,,,,,,,,,,,,,,,,,pAAV-hSyn-dLight1.2 Addgene Plasmid#: 111068 RRID: Addgene_111068 Gift on Lin Tian; produced by UC Davis Vector Core,Insert does not reference a core NF disease gene: dLight1.2
hChR2(H134R)-EYFP,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hChR2(H134R)-EYFP,Viral,AAV,hSyn,,,,,,,,,,,,,,,,,,pAAV-hSyn-hChR2(H134R)-EYFP Addgene Plasmid#: 26973 RRID: Addgene_26973 Gift of Karl Deisseroth,Insert does not reference a core NF disease gene: hChR2(H134R)-EYFP
Cre,genetic_reagents,PMID:31545171 | PMID:35589737 | PMID:20200958 | PMID:19191334 | PMID:28392281 | PMID:25772366 | PMID:23685747 | PMID:17924978 | PMID:38127282 | PMID:25043591,10.7554/eLife.48983 | 10.1038/s41467-022-30466-6 | 10.1002/jbmr.42 | 10.1002/glia.20845 | 10.1016/j.expneurol.2017.04.001 | 10.1016/j.celrep.2015.02.041 | 10.1038/ng.2641 | 10.1111/j.1750-3639.2007.00105.x | 10.1158/1078-0432.CCR-23-2548 | 10.1002/jbmr.2316,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Human stem cell modeling in neurofibromatosis type 1 (NF1). | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,AAV9,Th,,,,,,,,,,,,,,,,,,"AAV9-Th-PI-Cre-SV40 Addgene Plasmid#: 107788 RRID: Addgene_107788 Addgene viral prep#: 107788-AAV9 | DRG-NSCs were isolated from E13.5 embryo DRG/nerve roots, and were infected with Ad-CMV-Cre | infection with adenovirus Ad5-CMV-Cre or Ad5-CMV-eGFP (2500 viral particles per cell; Vector Development Lab) | The Nf1 gene was inactivated in passage 1 Nf1flox/flox astrocytes by infection with adenovirus (Ad5) containing Cre recombinase | excisable lentiviral vectors have been developed using Cre/loxP technology | Wild-type and Nf1 −/− NSCs were generated from Nf1 flox/flox mouse brains following infection with Ad5-LacZ and Ad5-Cre adenovirus | a Schwann cell specific Cre-recombinase controlled by the CNP promoter (Cnp-Cre) | Cre recombinase was targeted to the mouse leptomeninges by direct injection of 3 µL (1 × 10 8 plaque‐forming units) of adCre suspension | Cre recombinase expressing adenovirus (Ad5CMVCre-GFP High Titer, University of Iowa Viral Vector Core) | containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)",Insert does not reference a core NF disease gene: Cre
eNpHR3.0-eYFP,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,eNpHR3.0-eYFP,Viral,AAV-DJ,Ef1α,,,,,,,,,,,,,,,,,,pAAV-DJ-Ef1α-DO-eNpHR3.0-eYFP-WPRE-pA Addgene Plasmid#: 37087 RRID: Addgene_37087 Gift of Bernardo Sabatini,Insert does not reference a core NF disease gene: eNpHR3.0-eYFP
tTA,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,tTA,Viral,AAV,ihSyn1,,,,,,,,,,,,,,,,,,pAAV-ihSyn1-tTA-WPRE Addgene Plasmid#: 99120 RRID: Addgene_99120 | pAAV-Th-tTA-WPRE Addgene Plasmid#: 133268 RRID: Addgene_133268,Insert does not reference a core NF disease gene: tTA
iCAP-PHP.eB,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,iCAP-PHP.eB,Plasmid,pUCmini,,,,,,,,,,,,,,,,,,,pUCmini-iCAP-PHP.eB Addgene Plasmid#: 103005 RRID: Addgene_103005,Insert does not reference a core NF disease gene: iCAP-PHP.eB
dLight1,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dLight1,Viral,,,,,,,,,,,,,,,,,,,,We employed the genetically encoded optical dopamine sensor dLight1 to monitor dopaminergic neurotransmission in the ventral striatum of NF1 mice,Insert does not reference a core NF disease gene: dLight1
LacZ,genetic_reagents,PMID:32642734 | PMID:19191334 | PMID:25772366,10.1093/noajnl/vdz026 | 10.1002/glia.20845 | 10.1016/j.celrep.2015.02.041,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LacZ,Viral,,,,,,,,,,,,,,,,,,,,Cells were transduced with either lentiviral control shLacZ (Genome Institute at Washington University) | Control Nf1flox/flox astrocytes (wild-type) were treated identically with an adenovirus encoding LacZ | Wild-type and Nf1 −/− NSCs were generated from Nf1 flox/flox mouse brains following infection with Ad5-LacZ and Ad5-Cre adenovirus,Insert does not reference a core NF disease gene: LacZ
Trim23,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Trim23,Viral,,,,,,,,,,,,,,,,,,,,"separate lentiviral shRNAs targeting Trim23 (Sigma; TRCN0000308323, TRCN0000308321, TRCN0000308320)",Insert does not reference a core NF disease gene: Trim23
shCOL1A2,genetic_reagents,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shCOL1A2,Viral,,,,,,,,,,,,,,,,,,,,Human sh COL1A2 and mouse sh Col1a2 lentiviral particles (TRCN0000090043; TRCN0000090045; TRCN0000335210),Insert does not reference a core NF disease gene: shCOL1A2
truXTRAC FFPE DNA,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,truXTRAC FFPE DNA,Other,,,,,,,,,,,,,,,,,,,,DNA extraction from FFPE tissue samples was performed using the Covaris truXTRAC FFPE DNA kit with the E220 Evolution-focused ultrasonicator system,Insert does not reference a core NF disease gene: truXTRAC FFPE DNA
Kapa HyperPlus,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Kapa HyperPlus,Other,,,,,,,,,,,,,,,,,,,,"Exome libraries were prepared using the Roche Kapa HyperPlus kit, captured using the HyperExome kit Roche",Insert does not reference a core NF disease gene: Kapa HyperPlus
HumanMethylationEPIC,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HumanMethylationEPIC,Other,,,,,,,,,,,,,,,,,,,,Tumor DNA derived from fresh-frozen tumors and paired normal nerve samples was used for whole-genome DNA methylation array profiling using the HumanMethylationEPIC beadchip platform,Insert does not reference a core NF disease gene: HumanMethylationEPIC
EZ DNA methylation Gold,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EZ DNA methylation Gold,Other,,,,,,,,,,,,,,,,,,,,350 ng of DNA were bisulfite converted using the Zymo EZ DNA methylation Gold kit (Zymo Research Corp.),Insert does not reference a core NF disease gene: EZ DNA methylation Gold
PCR master mix,genetic_reagents,PMID:18670322 | PMID:21726432,10.1097/MLG.0b013e318177e20b | 10.1186/1741-7015-9-82,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PCR master mix,Other,,,,,,,,,,,,,,,,,,,,"Taqman Universal PCR Master Mix (2× buffer containing polymerase; Applied Biosystems, Foster City, CA) | TaqMan Universal PCR Master Mix was then performed on an ABI PRISM 7900 Cycler (Applied Biosystems)",Insert does not reference a core NF disease gene: PCR master mix
GLuc,genetic_reagents,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GLuc,Viral,,,,,,,,,,,,,,,,,,,,"NF2 −/− cells should be transduced before use so they express the GLuc reporter gene, which is a secreted reporter that can be detected in the blood of tumor-bearing animals. | GLuc vector and assay kits are commercially available from various biotech companies, such as Thermo Fisher Scientific (cat. no. 16146) and New England BioLabs (cat. no. N8084S).",Insert does not reference a core NF disease gene: GLuc
apterous-Gal4,genetic_reagents,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,apterous-Gal4,Other,,,,,,,,,,,,,,,,,,,,ectopic expression of the NF2 isoforms under the control of the apterous-Gal4 driver,Insert does not reference a core NF disease gene: apterous-Gal4
H-RAS,genetic_reagents,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,H-RAS,Plasmid,,,,,,,,,,,,,,,,,,,,HA-H-RAS was expressed together with either wild-type (WT) or variant NF in COS-7 or HEK 293 T cells,Insert does not reference a core NF disease gene: H-RAS
RAF-RBD,genetic_reagents,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RAF-RBD,Other,,,,,,,,,,,,,,,,,,,,GTP-bound RAS was subsequently isolated using glutathione-agarose beads coated with recombinant GST-RAF-RBD,Insert does not reference a core NF disease gene: RAF-RBD
BNIP3,genetic_reagents,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BNIP3,Other,,,,,,,,,,,,,,,,,,,,BNIP3 and HIF-1α siRNA (siGENOME SMARTPool) was purchased from Thermo Scientific,Insert does not reference a core NF disease gene: BNIP3
HIF-1α,genetic_reagents,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HIF-1α,Other,,,,,,,,,,,,,,,,,,,,BNIP3 and HIF-1α siRNA (siGENOME SMARTPool) was purchased from Thermo Scientific,Insert does not reference a core NF disease gene: HIF-1α
PrimeSTAR GXL,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PrimeSTAR GXL,,,,,,,,,,,,,,,,,,,,,"the targeted region was PCR amplified with the hotstart PrimeSTAR GXL DNA polymerase (Takara Bio Inc., Mountain View, CA)",Insert does not reference a core NF disease gene: PrimeSTAR GXL
NHE1,genetic_reagents,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NHE1,Other,,,,,,,,,,,,,,,,,,,,"NHE1 siRNA: ON-TARGET SMART pool (Thermo Scientific); NBCn1 siRNA (SASI_Hs01_00030755, Sigma-Aldrich)",Insert does not reference a core NF disease gene: NHE1
V-CSCW2,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,V-CSCW2,Viral,CSCW2,,,,,,,,,,,,,,,,,,,Ben-Men-1 cells were transduced with either NF2-CSCW2 or V-CSCW2,Insert does not reference a core NF disease gene: V-CSCW2
MM-121,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,MM-121,,,,,,,,,,,,,,,,,,,,,MM-121 (generously provided by Merrimack Pharmaceuticals),Insert does not reference a core NF disease gene: MM-121
SA3,genetic_reagents,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,SA3,,,,,,,,,,,,,,,,,,,,,"mice that were treated with the STING agonist SA3 (HY-103665, MedChemExpress)",Insert does not reference a core NF disease gene: SA3
GRDC24,genetic_reagents,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,GRDC24,Viral,AAV,CBh,,,,,,,,,,,,,,,,,,pscAAV-GFP and pscAAV-GRDC24 (2163 bp between ITRs) were used to generate AAV-GFP and AAV-GRDC24,Insert does not reference a core NF disease gene: GRDC24
NF-targeting capsid,genetic_reagents,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,NF-targeting capsid,Viral,AAV,,,,,,,,,,,,,,,,,,,"This tailored vector, AAV-NF, exhibits greatly reduced liver uptake, enhanced tumor targeting across various NF1-related MPNST",Insert does not reference a core NF disease gene: NF-targeting capsid
Human Phospho-RTK Array,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Phospho-RTK Array,Other,,,,,,,,,,,,,,,,,,,,"MPNST cells were seeded in 15-cm dishes, allowed cell attachment overnight, treated the next day with the desired drug concentrations, harvested at the experiment endpoint, and lysed using the lysis buffer provided by Human Phospho-RTK Array Kit (R&D)",Insert does not reference a core NF disease gene: Human Phospho-RTK Array
L-[18F]FETrp,genetic_reagents,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,L-[18F]FETrp,,,,,,,,,,,,,,,,,,,,,"We studied a fluorine-18 labeled tryptophan positron emission tomography (PET) radiotracer, 1-(2-[18F]FETrp",Insert does not reference a core NF disease gene: L-[18F]FETrp
PDLIM2 shRNA,genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PDLIM2 shRNA,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,Five different shRNA clones were tested... cloned into the plasmid pLKO.1-puro,Insert does not reference a core NF disease gene: PDLIM2 shRNA
λ-phosphatase,genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,λ-phosphatase,,,,,,,,,,,,,,,,,,,,,Protein dephosphorylation was achieved by treating 20 μg of protein lysate with λ-phosphatase (New England Biolabs),Insert does not reference a core NF disease gene: λ-phosphatase
Cre and gRNAs,genetic_reagents,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,Cre and gRNAs,Viral,pLenti,CMV,,,,,,,,,,,,,,,,,,"We then prepared lentivirus vector pLentiCre/gRNA, which could express the elements blocking the function of four genes: Nf2, P15 | we constructed an AAV vector of pAAVCre/gRNA, which could import Cre and the four gRNAs",Insert does not reference a core NF disease gene: Cre and gRNAs
MAF,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MAF,Viral,Lentivirus,,,,,,,,,,,,,,,,,,,"Constitutive expression used mCherry tagged MAF (EX-Y2046-Lv111, GeneCopoeia) and mCherry control lentivirus",Insert does not reference a core NF disease gene: MAF
MAF ORF,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MAF ORF,Viral,pLVX-Tight-Puro,,,,,,,,,,,,,,,,,,,Inducible expression used lentiviral vectors containing the MAF ORF or empty pLVX-Tight-Puro vector (GeneCopoeia),Insert does not reference a core NF disease gene: MAF ORF
shRHAMM,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRHAMM,Viral,,,,,,,,,,,,,,,,,,,,shRNA against RHAMM and TPX2 (Sigma),Insert does not reference a core NF disease gene: shRHAMM
shTPX2,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shTPX2,Viral,,,,,,,,,,,,,,,,,,,,shRNA against RHAMM and TPX2 (Sigma),Insert does not reference a core NF disease gene: shTPX2
ZEB1,genetic_reagents,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZEB1,Other,,,,,,,,,,,,,,,,,,,,"For siRNA knockdown targeting ZEB1 (Sigma-Aldrich, SASI_Hs02_00330526, SASI_Hs02_00330527, SASI_Hs02_00330530) | T265, was infected by nontarget control or lentiviral vectors carrying ZEB1 shRNA lentivirus for 48 hours",Insert does not reference a core NF disease gene: ZEB1
ALDH1A1,genetic_reagents,PMID:36322658 | PMID:36148553,10.1126/sciadv.abo5442 | 10.1093/brain/awac342,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ALDH1A1,Other,,,,,,,,,,,,,,,,,,,,"ALDH1A1 (Sigma-Aldrich, SASI_Hs01_00244055, SASI_Hs01_00244056, SASI_Hs02_00303091) in MPNST cell lines | ALDH1A1 (TRCN0000026415)—5′-GCCAAATCATTCCTTGGAATTT-3′",Insert does not reference a core NF disease gene: ALDH1A1
StrepII tag,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,StrepII tag,Other,,,,,,,,,,,,,,,,,,,,"We utilized a StepTactin XT System from IBA Lifesciences (Gottingen, Germany). Whole cell lysates were generated by collecting cells and lysing them",Insert does not reference a core NF disease gene: StrepII tag
M-PER,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,M-PER,Other,,,,,,,,,,,,,,,,,,,,"Global protein extracts were attained using M-PER™ Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, Cat.# 78501)",Insert does not reference a core NF disease gene: M-PER
BCA,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BCA,Other,,,,,,,,,,,,,,,,,,,,"and quantified using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Cat.# PI23225)",Insert does not reference a core NF disease gene: BCA
Gentamicin,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Gentamicin,,,,,,,,,,,,,,,,,,,,,Gentamicin (Sigma) and G418 (Corning) were reconstituted in sterile deionized water to a stock concentration of 50 mg/mL,Insert does not reference a core NF disease gene: Gentamicin
PBSB,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PBSB,Transposon,,,,,,,,,,,,,,,,,,,,we used Gateway cloning to transfer the DLR insert to a hygromycin-resistant PiggyBac Sleeping Beauty (PBSB) transposon vector,Insert does not reference a core NF disease gene: PBSB
UPF1,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,UPF1,Other,,,,,,,,,,,,,,,,,,,,"cells were transfected with 50 nm of siRNA targeting UPF1. In a pilot experiment, three custom and non-overlapping UPF1 duplexes were tested",Insert does not reference a core NF disease gene: UPF1
EdU,genetic_reagents,PMID:40684195 | PMID:34040258 | PMID:34010628,10.1186/s40478-025-02075-z | 10.1038/s41586-021-03580-6 | 10.1016/j.stem.2021.04.029,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU,,,,,,,,,,,,,,,,,,,,,"EdU detection was performed on 14 μm-thick cryosections using the Click-IT Plus EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific) | EdU proliferation assay was performed using the Click-iT EdU Alexa Fluor 594 imaging kit (Thermo Fisher Scientific C10339) | The incorporated EdU were stained on top of BrdU staining with Click-iT™ EdU Cell Proliferation Kit for Imaging (ThemoFisher, Cat# C10337)",Insert does not reference a core NF disease gene: EdU
Lipofectamine,genetic_reagents,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine,Other,,,,,,,,,,,,,,,,,,,,Neurite outgrowth was determined from low-density hippocampal neurons transfected with EGFP using Lipofectamine,Insert does not reference a core NF disease gene: Lipofectamine
hGFAP-cre,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hGFAP-cre,Other,,,,,,,,,,,,,,,,,,,,The control mice used in this study are a pool of phenotypically indistinguishable mice with genotypes of hGFAP-cre-; Nf1 flox/flox,Insert does not reference a core NF disease gene: hGFAP-cre
Nestin-cre ER,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Nestin-cre ER,,,,,,,,,,,,,,,,,,,,,"For inducible experiments, Nestin-cre ER +; Nf1 flox/+  (tamoxifen+) mice were used as controls while Nestin-cre ER +; Nf1 flox/flox",Insert does not reference a core NF disease gene: Nestin-cre ER
R26 LacZR,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,R26 LacZR,,,,,,,,,,,,,,,,,,,,,Both of inducible strains carry R26 LacZR  allele as a reporter.,Insert does not reference a core NF disease gene: R26 LacZR
human FBXW11,genetic_reagents,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,human FBXW11,Plasmid,,,,,,,,,,,,,,,,,,,,"Myc-DDK–tagged human FBXW11 transcript variant 3 cDNA (RC218905, Origene)",Insert does not reference a core NF disease gene: human FBXW11
Cre-GFP,genetic_reagents,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre-GFP,Viral,AAV5,CMV,,,,,,,,,,,,,,,,,,"control (GFP; AAV5-CMV-GFP, UNC) or Cre-recombinase fused to GFP (CRE; AAV5-CMV-Cre-GFP, UNC)",Insert does not reference a core NF disease gene: Cre-GFP
targeted region arrays,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,targeted region arrays,Other,,,,,,,,,,,,,,,,,,,,"We next designed custom NimbleGen targeted region arrays on five candidate genes, and sequenced four additional malignant meningiomas.",Insert does not reference a core NF disease gene: targeted region arrays
COMT val158met probe,genetic_reagents,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,COMT val158met probe,Other,,,,,,,,,,,,,,,,,,,,"Genotyping was performed using a real-time PCR system in the allelic discrimination mode...using the TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA, USA)",Insert does not reference a core NF disease gene: COMT val158met probe
Ras Binding Domain,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Ras Binding Domain,Other,,,,,,,,,,,,,,,,,,,,"To determine the activity of Ras the EZ-Detect Ras Activation Kit (cat. 89855 from Pierce, Rockford, IL) was used",Insert does not reference a core NF disease gene: Ras Binding Domain
B-Raf,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,B-Raf,Other,,,,,,,,,,,,,,,,,,,,"siRNA for either B-Raf: AAAGAATTGGATCTGGATCAT, and C-Raf: TGTGCGAAATGGAATGAGCTT, both from Dharmacon",Insert does not reference a core NF disease gene: B-Raf
C-Raf,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,C-Raf,Other,,,,,,,,,,,,,,,,,,,,"siRNA for either B-Raf: AAAGAATTGGATCTGGATCAT, and C-Raf: TGTGCGAAATGGAATGAGCTT, both from Dharmacon",Insert does not reference a core NF disease gene: C-Raf
P53 shRNA,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,P53 shRNA,Viral,Lentiviral,,,,,,,,,,,,,,,,,,,P53 (5′-GA CTCCA GTGGT AA TCT A C-3′),Insert does not reference a core NF disease gene: P53 shRNA
P53,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,P53,Plasmid,,,,,,,,,,,,,,,,,,,,Flag-tagged P53 (Addgene; #10838),Insert does not reference a core NF disease gene: P53
CXCL12,genetic_reagents,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CXCL12,Viral,,,,,,,,,,,,,,,,,,,,Murine CXCL12 cDNA was subcloned into the lentiviral vector,Insert does not reference a core NF disease gene: CXCL12
FLAG,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FLAG,Plasmid,,,,,,,,,,,,,,,,,,,,"Gateway LR recombination according to the manufacturer's protocol to insert NF1, SPRED1, and RAS entry clones into transient mammalian expression vectors pCAN-FLAG-DEST",Insert does not reference a core NF disease gene: FLAG
HA,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HA,Plasmid,,,,,,,,,,,,,,,,,,,,"Gateway LR recombination according to the manufacturer's protocol to insert NF1, SPRED1, and RAS entry clones into transient mammalian expression vectors pCAN-FLAG-DEST and pCAN-HA-DEST",Insert does not reference a core NF disease gene: HA
Tet-pLKO-puro,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet-pLKO-puro,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,"shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector (Addgene, no. 21915)",Insert does not reference a core NF disease gene: Tet-pLKO-puro
TTIGFP-MLUEX,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TTIGFP-MLUEX,Plasmid,,Tet-regulated promoter,,,,,,,,,,,,,,,,,,The human NF1-GRD was amplified using the genomic deoxyribonucleic acid (gDNA) from HEK293T as polymerase chain reaction template and subcloned into TTIGFP-MLUEX vector,Insert does not reference a core NF disease gene: TTIGFP-MLUEX
shPTPN11,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shPTPN11,Plasmid,pLKO,Tet-regulated,,,,,,,,,,,,,,,,,,shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector,Insert does not reference a core NF disease gene: shPTPN11
SB11,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SB11,Other,,,,,,,,,,,,,,,,,,,,a conditionally expressed SB transposase enzyme (R26-lsl-SB11),Insert does not reference a core NF disease gene: SB11
T2/Onc15,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,T2/Onc15,Transposon,,,,,,,,,,,,,,,,,,,,a concatomer of oncogenic transposons (T2/Onc15),Insert does not reference a core NF disease gene: T2/Onc15
EGFR,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,EGFR,,,CNP,,,,,,,,,,,,,,,,,,"MPNST predisposing alleles, Cnp-EGFR and conditional Trp53 alleles",Insert does not reference a core NF disease gene: EGFR
FOXR2,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FOXR2,Transposon,piggyBac,,,,,,,,,,,,,,,,,,,FOXR2 cDNA (Open Biosystems) was cloned into the Gateway Vector System (Invitrogen) and subcloned into a piggyBac (PB) transposon vector | TALENs targeting FOXR2 were designed using TALE-NT and constructed,Insert does not reference a core NF disease gene: FOXR2
HPRT,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HPRT,Other,,,,,,,,,,,,,,,,,,,,An HPRT TALEN pair served as a control,Insert does not reference a core NF disease gene: HPRT
KCNMA1,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KCNMA1,Other,,,,,,,,,,,,,,,,,,,,QuantiTech Qiagen primers:  KCNMA1  (cat# QT00024157),Insert does not reference a core NF disease gene: KCNMA1
PRKCE,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PRKCE,Other,,,,,,,,,,,,,,,,,,,,PRKCE  (cat# QT00016352),Insert does not reference a core NF disease gene: PRKCE
OPCML,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,OPCML,Other,,,,,,,,,,,,,,,,,,,,OPCML  (cat# QT01005361),Insert does not reference a core NF disease gene: OPCML
GRIK2,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GRIK2,Other,,,,,,,,,,,,,,,,,,,,GRIK2  (cat# QT00016597),Insert does not reference a core NF disease gene: GRIK2
CADM2,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CADM2,Other,,,,,,,,,,,,,,,,,,,,CADM2  (cat# QT00048888),Insert does not reference a core NF disease gene: CADM2
CREB5,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CREB5,Other,,,,,,,,,,,,,,,,,,,,CREB5  (cat# QT00054488),Insert does not reference a core NF disease gene: CREB5
CAMK1D,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CAMK1D,Other,,,,,,,,,,,,,,,,,,,,CAMK1D  (cat# QT00036344),Insert does not reference a core NF disease gene: CAMK1D
ITGB8,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ITGB8,Other,,,,,,,,,,,,,,,,,,,,ITGB8  (cat# QT00038507),Insert does not reference a core NF disease gene: ITGB8
Klenow (exo-),genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Klenow (exo-),Other,,,,,,,,,,,,,,,,,,,,"42 µl of end-repaired DNA was mixed with 5 µl of 10 X dA Tailing Reaction Buffer and 3 µl of Klenow (exo-)(cat# E6053, NEB, Ipswich, MA).",Insert does not reference a core NF disease gene: Klenow (exo-)
anti-HER1 CAR 806,genetic_reagents,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,anti-HER1 CAR 806,Viral,,,,,,,,,,,,,,,,,,,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)",Insert does not reference a core NF disease gene: anti-HER1 CAR 806
anti-HER1 CAR E2,genetic_reagents,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,anti-HER1 CAR E2,Viral,,,,,,,,,,,,,,,,,,,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)",Insert does not reference a core NF disease gene: anti-HER1 CAR E2
anti-HER1 CAR NEC,genetic_reagents,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,anti-HER1 CAR NEC,Viral,,,,,,,,,,,,,,,,,,,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)",Insert does not reference a core NF disease gene: anti-HER1 CAR NEC
AHR,genetic_reagents,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AHR,Other,,,,,,,,,,,,,,,,,,,,siRNA targeting...AHR (s1200),Insert does not reference a core NF disease gene: AHR
PB7 transposase,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PB7 transposase,,,CMV,,,,,,,,,,,,,,,,,,500 ng of CMV-PB7 transposase,Insert does not reference a core NF disease gene: PB7 transposase
Human Universal Reference RNA,genetic_reagents,PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Human Universal Reference RNA,,,,,,,,,,,,,,,,,,,,,"Sample RNA was processed in triplicate with serial dilutions of Human Universal Reference RNA (Stratagene, La Jolla, CA, USA)",Insert does not reference a core NF disease gene: Human Universal Reference RNA
SGK1,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SGK1,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,pLKO-puro-based shRNAs targeting human SGK1 (TRCN0000194957),Insert does not reference a core NF disease gene: SGK1
PAK1,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PAK1,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,human PAK1 (TRCN0000197238),Insert does not reference a core NF disease gene: PAK1
RHEB,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RHEB,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,human RHEB (TRCN0000010424),Insert does not reference a core NF disease gene: RHEB
Ultra Low Cluster Plates,genetic_reagents,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ultra Low Cluster Plates,,,,,,,,,,,,,,,,,,,,,plated in 0.34% low melting temperature agarose (FMC Bioproducts) in complete medium at 2×10 4 (Meso-33 cells) or 1.2×10 4 (FC-1801 cells) per well in 24-well Ultra Low Cluster Plates (Costar).,Insert does not reference a core NF disease gene: Ultra Low Cluster Plates
GST-PID,genetic_reagents,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GST-PID,Plasmid,,,,,,,,,,,,,,,,,,,,A GST-PID (Pak1 amino acids 83–149) or Gst-PID L107F cDNA was subcloned,Insert does not reference a core NF disease gene: GST-PID
Gst-PID L107F,genetic_reagents,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gst-PID L107F,Plasmid,,,,,,,,,,,,,,,,,,,,A GST-PID (Pak1 amino acids 83–149) or Gst-PID L107F cDNA was subcloned,Insert does not reference a core NF disease gene: Gst-PID L107F
PTPN11,genetic_reagents,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PTPN11,Other,,,,,,,,,,,,,,,,,,,,"SMARTPool ON-TARGETplus Human PTPN11 siRNA (#L-003947–00-0005, Dharmacon) to knockdown (KD) the expression of non-targeting control (NTC) and SHP2",Insert does not reference a core NF disease gene: PTPN11
I2HCP panel,genetic_reagents,PMID:28051113 | PMID:36420221,10.1038/srep39348 | 10.1016/j.omtn.2022.10.026,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype",,0.9,Development,False,1.00,Medium,,,,,,,,,,,I2HCP panel,Other,,,,,,,,,,,,,,,,,,,,"we developed the I2HCP panel, a custom bait library covering 122 hereditary cancer genes | Genetic testing was performed using the customized I2HCP panel in blood or tissue when available.",Insert does not reference a core NF disease gene: I2HCP panel
β-catenin ΔN90,genetic_reagents,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,β-catenin ΔN90,Viral,,,,,,,,,,,,,,,,,,,,"β-catenin overexpression lentivirus ΔN90 (Addgene, Cambridge MA)",Insert does not reference a core NF disease gene: β-catenin ΔN90
D22S193,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S193,Other,,,,,,,,,,,,,,,,,,,,checked for loss of heterozygosity in tumor DNA at markers D22S193 (centromeric to NF2),Insert does not reference a core NF disease gene: D22S193
D22S929,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S929,Other,,,,,,,,,,,,,,,,,,,,"NF2 TET and D22S929 (intragenic), and D22S268 and D22S430",Insert does not reference a core NF disease gene: D22S929
D22S268,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S268,Other,,,,,,,,,,,,,,,,,,,,"D22S929 (intragenic), and D22S268 and D22S430 (telomeric to NF2)",Insert does not reference a core NF disease gene: D22S268
D22S430,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S430,Other,,,,,,,,,,,,,,,,,,,,and D22S268 and D22S430 (telomeric to NF2),Insert does not reference a core NF disease gene: D22S430
BstUI,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BstUI,Other,,,,,,,,,,,,,,,,,,,,"PCR products were then digested using the endonuclease BstUI in 30 μl volumes according to the manufacturer's specifications (New England Biolabs, Beverly, MA)",Insert does not reference a core NF disease gene: BstUI
biocytin,genetic_reagents,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,biocytin,,,,,,,,,,,,,,,,,,,,,0.2% biocytin was included in the intracellular pipette solution for later morphological identification,Insert does not reference a core NF disease gene: biocytin
HumanOmni2.5-8,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HumanOmni2.5-8,Other,,,,,,,,,,,,,,,,,,,,"SNP array sample prep was done using the HumanOmni2.5–8 (Illumina, Inc., San Diego, CA, USA)",Insert does not reference a core NF disease gene: HumanOmni2.5-8
Endo-Porter,genetic_reagents,PMID:36420221 | PMID:29670214,10.1016/j.omtn.2022.10.026 | 10.1038/s41598-018-24310-5,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Endo-Porter,Other,,,,,,,,,,,,,,,,,,,,"Endo-Porter (Gene Tools) was used as vehicle to deliver PMOs into cells at 6 μM | SynNF1 was transduced into fibroblasts using the transduction reagent EndoPorter (GeneTools, LLC)",Insert does not reference a core NF disease gene: Endo-Porter
interferon alpha-2b,genetic_reagents,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,interferon alpha-2b,Other,,,,,,,,,,,,,,,,,,,,PEGylated interferon alpha-2b was purchased at the Cincinnati Children's Hospital (National Drug Code 00085132302) pharmacy,Insert does not reference a core NF disease gene: interferon alpha-2b
shSOX9,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shSOX9,Viral,,,,,,,,,,,,,,,,,,,,we infected MPNST cells at 70–90% confluence with lentiviral particles containing shRNAs targeting SOX9 (Open Biosystems; TRC library),Insert does not reference a core NF disease gene: shSOX9
hTERT and mCdk4,genetic_reagents,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hTERT and mCdk4,Viral,pTYcPPT,EF1α,,,,,,,,,,,,,,,,,,"The vector pTYcPPT, containing the elongation factor 1 alpha promoter, was used to separately clone hTERT and mCdk4",Insert does not reference a core NF disease gene: hTERT and mCdk4
hTERT,genetic_reagents,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hTERT,Viral,,,,,,,,,,,,,,,,,,,,full length human telomerase reverse transcriptase cDNA,Insert does not reference a core NF disease gene: hTERT
mCdk4,genetic_reagents,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mCdk4,Viral,,,,,,,,,,,,,,,,,,,,murine Cdk4 full-length cDNA,Insert does not reference a core NF disease gene: mCdk4
KIF15/KIF23 siRNA,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KIF15/KIF23 siRNA,Other,,,,,,,,,,,,,,,,,,,,"siRNA pool targeting KIF15, KIF23, or a non-targeting control (NTC; siGENOME SMARTpool, Dharmacon)",Insert does not reference a core NF disease gene: KIF15/KIF23 siRNA
RGS2,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RGS2,Plasmid,,,,,,,,,,,,,,,,,,,,pRGS2 surrogate reporter (Labomics),Insert does not reference a core NF disease gene: RGS2
ispinesib,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,ispinesib,,,,,,,,,,,,,,,,,,,,,"ispinesib (Selleckchem) or ARRY-520 (MedChemExpress), which selectively inhibit KIF11",Insert does not reference a core NF disease gene: ispinesib
HiTrap Chelating Sepharose™ High Performance,genetic_reagents,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,HiTrap Chelating Sepharose™ High Performance,Other,,,,,,,,,,,,,,,,,,,,The supernatant ran through a 5 ml HiTrap Chelating Sepharose™ High Performance (GE healthcare) and washed extensively,Insert does not reference a core NF disease gene: HiTrap Chelating Sepharose™ High Performance
Superdex 200 10/300 GL column,genetic_reagents,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Superdex 200 10/300 GL column,Other,,,,,,,,,,,,,,,,,,,,Further purification followed by gel filtration chromatography using a Superdex 200 10/300 GL column (GE Healthcare),Insert does not reference a core NF disease gene: Superdex 200 10/300 GL column
Gd-DTPA,genetic_reagents,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Gd-DTPA,,,,,,,,,,,,,,,,,,,,,"all animals were intraperitoneally injected (1) a MR contrast agent, Gd-DTPA (Magnevist ®, Schering, Leverkusen, Germany) at a dose of 0.8 mL/kg",Insert does not reference a core NF disease gene: Gd-DTPA
Human Mapping 100K Set,genetic_reagents,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Mapping 100K Set,Other,,,,,,,,,,,,,,,,,,,,Tumor genotyping was performed with the Human Mapping 100K Set platform ( Affymetrix ),Insert does not reference a core NF disease gene: Human Mapping 100K Set
GeneChip Human Genome U133 Plus 2.0 Arrays,genetic_reagents,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GeneChip Human Genome U133 Plus 2.0 Arrays,Other,,,,,,,,,,,,,,,,,,,,gene-expression data were obtained using GeneChip Human Genome U133 Plus 2.0 Arrays ( Affymetrix ),Insert does not reference a core NF disease gene: GeneChip Human Genome U133 Plus 2.0 Arrays
PDE4A1,genetic_reagents,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,PDE4A1,Viral,,,,,,,,,,,,,,,,,,,,Full-length murine PDE4A1 or catalytically inactive PDE4A1-H229Q was cloned into a lentiviral packaging vector that also encodes mCherry fluorescent protein,Insert does not reference a core NF disease gene: PDE4A1
PDE4A1-H229Q,genetic_reagents,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,PDE4A1-H229Q,Viral,,,,,,,,,,,,,,,,,,,,Full-length murine PDE4A1 or catalytically inactive PDE4A1-H229Q was cloned into a lentiviral packaging vector that also encodes mCherry fluorescent protein,Insert does not reference a core NF disease gene: PDE4A1-H229Q
PAM71,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,PAM71,,,,,,,,,,,,,,,,,,,,,"PAM71 (MedChemExpress, catalog HY-134494), 8-(4-Chlorophenylthio)adenosine",Insert does not reference a core NF disease gene: PAM71
MLPA probe set,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MLPA probe set,Other,,,,,,,,,,,,,,,,,,,,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used",Insert does not reference a core NF disease gene: MLPA probe set
Kit Ligand,genetic_reagents,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Kit Ligand,,,,,,,,,,,,,,,,,,,,,"To determine if ketotifen had an in vivo effect on mast cell infiltration and degranulation, four-month old Nf1 mice were administered subcutaneous Kit Ligand as previously described",Insert does not reference a core NF disease gene: Kit Ligand
dCas9-BFP-KRAB,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dCas9-BFP-KRAB,Plasmid,pMH0001,SFFV,,,,,,,,,,,,,,,,,,"Lentivirus containing pMH0001 (UCOE-SFFV-dCas9-BFP-KRAB, #85969, Addgene) was produced",Insert does not reference a core NF disease gene: dCas9-BFP-KRAB
TAZ,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TAZ,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,TAZ (TRCN0000307197)—5′-CGGACTTCATTCAAGAGGAAT-3′,Insert does not reference a core NF disease gene: TAZ
YAP,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,YAP,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,YAP (TRCN0000107266)—5′-GCCACCAAGCTAGATAAAGAA-3′,Insert does not reference a core NF disease gene: YAP
IPA-3,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,IPA-3,,,,,,,,,,,,,,,,,,,,,Cells were treated with IPA-3 (Sigma-Aldrich) a PAK group1 inhibitor (PAK1/2/3),Insert does not reference a core NF disease gene: IPA-3
PMOs,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PMOs,Other,,,,,,,,,,,,,,,,,,,,"The 25-mer-specific PMOs for four patients with splicing variants, and a pair of PMOs to induce exon skipping of exons 4, 8, and 11 of the NF2 gene were designed",Insert does not reference a core NF disease gene: PMOs
Gateway Gene Cloning system,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gateway Gene Cloning system,Other,,,,,,,,,,,,,,,,,,,,The NF2 gene was cloned using the Gateway Gene Cloning system (Invitrogen) after treatment to induce the exon-skipping to an FLAG Tag Expression Vector,Insert does not reference a core NF disease gene: Gateway Gene Cloning system
FLAG Tag,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FLAG Tag,Plasmid,,,,,,,,,,,,,,,,,,,,The NF2 gene was cloned using the Gateway Gene Cloning system (Invitrogen) after treatment to induce the exon-skipping to an FLAG Tag Expression Vector,Insert does not reference a core NF disease gene: FLAG Tag
Lipofectamine LTX,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine LTX,Other,,,,,,,,,,,,,,,,,,,,"The expression vector was transfected into HeLa cells (Lipofectamine LTX with Plus Reagent, Invitrogen)",Insert does not reference a core NF disease gene: Lipofectamine LTX
NeuroD1,genetic_reagents,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NeuroD1,Viral,,CMV,,,,,,,,,,,,,,,,,,"AdCMVNeuroD1 at 2 × 109 pfu/mL, or AdCMVNeuroD1 at 5 × 109 pfu/mL (ViraQuest, Inc.) were applied to the culture medium",Insert does not reference a core NF disease gene: NeuroD1
WC-10,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,WC-10,,,,,,,,,,,,,,,,,,,,,"[3H]-WC-10, and [3H]-a-Dihydrotetrabenazine ([3H]-DTBZ; American Radiolabeled Chemicals; St. Louis, MO)",Insert does not reference a core NF disease gene: WC-10
telomere repeat sequence probe,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,telomere repeat sequence probe,,,,,,,,,,,,,,,,,,,,,hybridization with a Cy3-labeled peptide nucleic acid (PNA) probe complementary to the mammalian telomere repeat sequence [(N-terminus to C-terminus) CCCTAACCCTAACCCTAA],Insert does not reference a core NF disease gene: telomere repeat sequence probe
centromeric DNA repeats probe,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,centromeric DNA repeats probe,,,,,,,,,,,,,,,,,,,,,an Alexa Fluor-488–labeled PNA probe specific to human centromeric DNA repeats was also included as a control to assess the validity of the hybridization,Insert does not reference a core NF disease gene: centromeric DNA repeats probe
644 cancer gene panel,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,644 cancer gene panel,Other,,,,,,,,,,,,,,,,,,,,Genomic regions of interest were captured using an Agilent custom-designed bait set covering the full coding regions of 644 cancer associated genes,Insert does not reference a core NF disease gene: 644 cancer gene panel
DUSP6,genetic_reagents,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,DUSP6,,,,,,,,,,,,,,,,,,,,,using the following pig TaqMan primers ( DUSP6 -Ss06941845_m1;  FOS  -Ss03390402_m1; normalized to the average of pig housekeeping genes,Insert does not reference a core NF disease gene: DUSP6
FOS,genetic_reagents,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,FOS,,,,,,,,,,,,,,,,,,,,,using the following pig TaqMan primers ( DUSP6 -Ss06941845_m1;  FOS  -Ss03390402_m1; normalized to the average of pig housekeeping genes,Insert does not reference a core NF disease gene: FOS
Tp53,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tp53,Other,,,,,,,,,,,,,,,,,,,,Cells were nucleofected with siRNA against Tp53 or miR34a (Dharmacon),Insert does not reference a core NF disease gene: Tp53
miR34a,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,miR34a,Other,,,,,,,,,,,,,,,,,,,,Cells were nucleofected with siRNA against Tp53 or miR34a (Dharmacon),Insert does not reference a core NF disease gene: miR34a
PHA,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PHA,Other,,,,,,,,,,,,,,,,,,,,Lymphocyte growth was stimulated with 50 µl/ml PHA (Gibco),Insert does not reference a core NF disease gene: PHA
IL-2,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,IL-2,Other,,,,,,,,,,,,,,,,,,,,stimulated with 50 µl/ml PHA (Gibco) and 10 units/ml of IL-2 (Roche),Insert does not reference a core NF disease gene: IL-2
MBP fusion,genetic_reagents,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MBP fusion,Plasmid,pMAL-c2X,,,,,,,,,,,,,,,,,,,The cDNA fragments were cloned in pMAL-c2X vector (New England Biolabs) for the expression of recombinant proteins as MBP fusions,Insert does not reference a core NF disease gene: MBP fusion
His-p55,genetic_reagents,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,His-p55,Other,,,,,,,,,,,,,,,,,,,,Bacterially expressed His-p55 was immobilized on the CM5 sensor chip,Insert does not reference a core NF disease gene: His-p55
REPLI-g FFPE,genetic_reagents,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,REPLI-g FFPE,,,,,,,,,,,,,,,,,,,,,genomic DNA was isolated and subjected to whole genome amplification according to manufacturers instructions using the REPLI-g FFPE kit (Qiagen),Insert does not reference a core NF disease gene: REPLI-g FFPE
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,"The first vectors used to generate iPSCs were gamma retroviruses, specifically murine leukemia retroviruses, chosen for their favorable long-term transgene expression | Lentiviral vectors, a retroviral subclass, can transduce both non-dividing and rapidly-dividing cells with efficiencies comparable to other retroviruses | Adenoviral vectors are considered a non-integrative option for reprogramming factor delivery | Sendai viral vectors are another non-integrative reprogramming alternative",Insert does not reference a core NF disease gene: reprogramming factors
"OCT4, SOX2, MYC, KLF4, NANOG, LIN28",genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,"OCT4, SOX2, MYC, KLF4, NANOG, LIN28",Plasmid,oriP/EBNA1,,,,,,,,,,,,,,,,,,,"human fibroblasts have been successfully reprogrammed after a single transfection with oriP/EBNA1 (Epstein-Barr nuclear antigen-1)-based episomal vectors expressing OCT4, SOX2, MYC, KLF4, NANOG, LIN28","Insert does not reference a core NF disease gene: OCT4, SOX2, MYC, KLF4, NANOG, LIN28"
pac,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pac,Viral,MSCV,,,,,,,,,,,,,,,,,,,a virus expressing the selectable marker gene alone (MSCV-pac),Insert does not reference a core NF disease gene: pac
c-abl siRNA,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,c-abl siRNA,Other,,,,,,,,,,,,,,,,,,,,"c-abl siRNA oligonucleotides (Cat. no. sc-29844) were purchased from Santa Cruz Biotechnology, Inc.",Insert does not reference a core NF disease gene: c-abl siRNA
Rictor,genetic_reagents,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Rictor,Viral,lentiviral,,,,,,,,,,,,,,,,,,,"cells were transfected with the control lentivirus (LV-vector), NF-1 sgRNA-CAS9 lentivirus (LV-NF-1), Rictor sgRNA-CAS9 lentivirus (LV-Rictor)",Insert does not reference a core NF disease gene: Rictor
TUNEL,genetic_reagents,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TUNEL,Other,,,,,,,,,,,,,,,,,,,,"The TUNEL assay was conducted by using the TUNEL kit (Roche, Reinach, Switzerland)",Insert does not reference a core NF disease gene: TUNEL
Rac1 N17,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rac1 N17,,,,,,,,,,,,,,,,,,,,,dominant-negative Rac1 (Rac1 N17) as previously described [15],Insert does not reference a core NF disease gene: Rac1 N17
Custom gene panel,genetic_reagents,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Custom gene panel,Other,,,,,,,,,,,,,,,,,,,,Transcript level of the following genes were analyzed using an Illumina custom panel,Insert does not reference a core NF disease gene: Custom gene panel
Alexa Fluor 594-labeled dextrans,genetic_reagents,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Alexa Fluor 594-labeled dextrans,,,,,,,,,,,,,,,,,,,,,"we electroporated the afferent fibers to the calyx of Held with Alexa Fluor 594-labeled dextrans (10,000 MW; Invitrogen)",Insert does not reference a core NF disease gene: Alexa Fluor 594-labeled dextrans
CEP 8 (D8Z2),genetic_reagents,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CEP 8 (D8Z2),Other,,,,,,,,,,,,,,,,,,,,Probes used were a centromeric-enumerating probe Vysis CEP 8 (D8Z2) SpectrumGreen combined with locus-specific probe,Insert does not reference a core NF disease gene: CEP 8 (D8Z2)
LSI MYC,genetic_reagents,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LSI MYC,Other,,,,,,,,,,,,,,,,,,,,combined with locus-specific probe Vysis LSI MYC SpectrumOrange (Abbott Molecular),Insert does not reference a core NF disease gene: LSI MYC
PSME3,genetic_reagents,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PSME3,Plasmid,pSG5,SV40,,,,,,,,,,,,,,,,,,stably transfected with plasmid pSG5 vector and encoding PSME3 cDNA harbor PA28у cDNA under a constitutive SV40 promotor,Insert does not reference a core NF disease gene: PSME3
Ref-1,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Ref-1,Other,,,,,,,,,,,,,,,,,,,,"MPNST cells were transfected with Ref-1 #1 siRNA (sequence previously reported) | LifeTech validated Ref-1 siRNA (s1447, Santa Cruz, Dallas, TX, USA)",Insert does not reference a core NF disease gene: Ref-1
STAT3,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,STAT3,Other,,,,,,,,,,,,,,,,,,,,"validated STAT3 siRNAs (sc-44275, sc-29493) and scrambled control",Insert does not reference a core NF disease gene: STAT3
